JP2021534094A5 - - Google Patents

Info

Publication number
JP2021534094A5
JP2021534094A5 JP2021506465A JP2021506465A JP2021534094A5 JP 2021534094 A5 JP2021534094 A5 JP 2021534094A5 JP 2021506465 A JP2021506465 A JP 2021506465A JP 2021506465 A JP2021506465 A JP 2021506465A JP 2021534094 A5 JP2021534094 A5 JP 2021534094A5
Authority
JP
Japan
Prior art keywords
once
alk
weeks
alk inhibitor
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021506465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534094A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/000905 external-priority patent/WO2020030977A2/en
Publication of JP2021534094A publication Critical patent/JP2021534094A/ja
Publication of JP2021534094A5 publication Critical patent/JP2021534094A5/ja
Pending legal-status Critical Current

Links

JP2021506465A 2018-08-07 2019-08-07 未分化リンパ腫キナーゼ阻害剤と組み合わせてｅｇｆ／ｅｇｆｒ経路を抑制するための方法および組成物 Pending JP2021534094A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862715351P 2018-08-07 2018-08-07
US62/715,351 2018-08-07
US201862727056P 2018-09-05 2018-09-05
US62/727,056 2018-09-05
US201862748772P 2018-10-22 2018-10-22
US62/748,772 2018-10-22
US201862760529P 2018-11-13 2018-11-13
US62/760,529 2018-11-13
US201962822290P 2019-03-22 2019-03-22
US62/822,290 2019-03-22
PCT/IB2019/000905 WO2020030977A2 (en) 2018-08-07 2019-08-07 Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2021534094A JP2021534094A (ja) 2021-12-09
JP2021534094A5 true JP2021534094A5 (enExample) 2022-08-12

Family

ID=68425157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506465A Pending JP2021534094A (ja) 2018-08-07 2019-08-07 未分化リンパ腫キナーゼ阻害剤と組み合わせてｅｇｆ／ｅｇｆｒ経路を抑制するための方法および組成物

Country Status (11)

Country Link
US (1) US12257245B2 (enExample)
EP (1) EP3833384A2 (enExample)
JP (1) JP2021534094A (enExample)
KR (1) KR20210041571A (enExample)
CN (1) CN112996534B (enExample)
AU (1) AU2019319109A1 (enExample)
BR (1) BR112021002145A2 (enExample)
CA (1) CA3108236A1 (enExample)
IL (1) IL280632A (enExample)
MX (1) MX2021001398A (enExample)
WO (1) WO2020030977A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112300284B (zh) * 2020-12-29 2021-04-06 慈达(广州)生物技术有限公司 核酸筛选结合抗体检测用于癌症检测中的用途及其制备的试剂盒
WO2022256360A1 (en) * 2021-06-02 2022-12-08 Neuvogen, Inc. Tumor cell vaccines
WO2023059801A1 (en) * 2021-10-06 2023-04-13 The Regents Of The University Of Colorado, A Body Corporate Biomarkers for egfr-mediated resistance in oncogene-driven cancers and methods of treating, preventing, and/or ameliorating oncogene-driven cancers
KR102685187B1 (ko) 2021-10-15 2024-07-16 제이투에이치바이오텍 (주) Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
CA3236522A1 (en) * 2021-10-28 2023-05-04 In3Bio Ltd. Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors
WO2023138576A1 (zh) * 2022-01-18 2023-07-27 齐鲁制药有限公司 螺环芳基磷氧化物与抗egfr抗体的药物组合
WO2024017352A1 (zh) * 2022-07-22 2024-01-25 四川大学 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒
WO2024249331A1 (en) * 2023-05-26 2024-12-05 The Board Of Regents Of The University Of Texas System Combined rtk and alk inhibition in rtk driven cancers
KR20250120789A (ko) 2024-02-02 2025-08-11 제이투에이치바이오텍 (주) E3 리가제 리간드 화합물, alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
US8828391B2 (en) * 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
SG11201400724SA (en) * 2011-09-19 2014-04-28 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists
RS54689B1 (sr) 2012-03-06 2016-08-31 Cephalon, Inc. Spojeni biciklični 2,4- diaminopirimidin derivat kao dualni alk i fak inhibitor
EP2890815B1 (en) * 2012-08-31 2019-03-20 The Regents of the University of Colorado Methods for diagnosis and treatment of cancer
US20160017431A1 (en) * 2014-03-28 2016-01-21 Driver Group Methods for Predicting EGFR Tyrosine Kinase Inhibitor Efficacy
SG11201608303QA (en) * 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
US12595297B2 (en) 2015-05-12 2026-04-07 In3Bio Ltd. Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors
MX2017015937A (es) * 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
JP2018521019A (ja) * 2015-06-08 2018-08-02 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体を使用して癌を治療する方法
JP7751357B2 (ja) 2017-07-18 2025-10-08 イン３バイオ・リミテッド 合成タンパク質およびその治療学的用途
RU2654695C1 (ru) 2017-07-28 2018-05-22 Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") 8-(1-{ 4-{ (5-Хлор-4-{ (2-(диметилфосфорил)фенил)амино} пиримидин-2-ил)амино)-3-метоксифенил} пиперидин-4-ил)-1-метил-1,8-диазаспиро(4.5)декан-2-он и его фармацевтически приемлемые соли в качестве модулятора ALK и EGER, предназначенные для лечения рака

Similar Documents

Publication Publication Date Title
JP2021534094A5 (enExample)
JP2024526145A5 (enExample)
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
US11932688B2 (en) Treatment for neoplastic diseases
US20180036395A1 (en) Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies
JP2018109022A5 (enExample)
JP2019517549A5 (enExample)
JP2008528486A5 (enExample)
WO2020030977A3 (en) Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors
JP2009544610A5 (enExample)
CN111166878B (zh) 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途
JP2021523096A5 (enExample)
ES2991384T3 (es) Composición farmacéutica, formulación farmacéutica combinada y kit de formulación combinada para la prevención o el tratamiento de la hepatitis B crónica, que comprende cada uno, como ingrediente activo, un agente antiviral oral y una vacuna terapéutica que incluye un lipopéptido y un adyuvante poli(I:C)
RU2020134183A (ru) Способ ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы
TW202535477A (zh) 抗ｂ７ｈ３抗體—藥物偶聯物治療癌症的方法
JP2024511977A5 (enExample)
TW202528000A (zh) 人類表皮生長因子第二型受體疫苗組成物以及套組
RU2021105387A (ru) Способы и композиции для подавления пути egf/egfr в комбинации с ингибиторами киназы анапластической лимфомы
CN120202006A (zh) 卡帕塞替尼和维奈托克的治疗组合
WO2013018018A1 (en) Antitumour combination comprising ombrabulin and cetuximab, associated with radiotherapy
HK40002544B (en) Treatment for neoplastic diseases
Fotin-Mleczek et al. 1253 POSTER Two-component Messenger RNA-based Vaccines Provide Strong Anti-tumoral Effect Especially in Combination With Radiation Therapy
WO2013018017A1 (en) Antitumour combination comprising ombrabulin and cisplatin, associated with radiotherapy
HK1229696A1 (en) Treatment for neoplastic diseases
HK1229696B (en) Treatment for neoplastic diseases